UBS Group
ENFN

UBS Group’s Enfusion, Inc. ENFN Stock Holding History

UBS Group’s Portfolio ENFN Stock Details ENFN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,663,802
Closed -$18.6M – 11166
2025
Q1 		$18.6M Buy
1,663,802
+1,589,237
+2,131% +$17.6M ﹤0.01% 2405
2024
Q4 		$768K Buy
74,565
+16,337
+28% +$158K ﹤0.01% 5519
2024
Q3 		$553K Buy
58,228
+39,085
+204% +$337K ﹤0.01% 5156
2024
Q2 		$163K Sell
19,143
-25,047
-57% -$229K ﹤0.01% 5809
2024
Q1 		$409K Buy
44,190
+19,407
+78% +$171K ﹤0.01% 5359
2023
Q4 		$240K Buy
24,783
+16,869
+213% +$158K ﹤0.01% 5652
2023
Q3 		$71K Sell
7,914
-8,193
-51% -$77.8K ﹤0.01% 6069
2023
Q2 		$181K Buy
16,107
+3,468
+27% +$30.7K ﹤0.01% 5552
2023
Q1 		$133K Buy
12,639
+6,435
+104% +$70.9K ﹤0.01% 5690
2022
Q4 		$60K Buy
6,204
+5,723
+1,190% +$64.4K ﹤0.01% 6587
2022
Q3 		$6K Buy
+481
New +$5.87K ﹤0.01% 9087
2022
Q2 		– Sell
-1,636
Closed -$21K – 11087
2022
Q1 		$21K Sell
1,636
-4,500
-73% -$68.7K ﹤0.01% 7412
2021
Q4 		$128K Buy
+6,136
New +$124K ﹤0.01% 6077

Other funds holding ENFN

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group's ENFN Position: Q2 2025 in Review

UBS Group sold out of Enfusion, Inc. (ENFN) in Q2 2025, closing a stake of 1,663,802 shares — an estimated $18.6M sold.

UBS Group first reported a position in ENFN in Q4 2021 and held it in 13 quarters. The position peaked at $18.6M in Q1 2025. 2 funds tracked by Wall St. Rank hold ENFN as of Q2 2025.

  • UBS Group reported no remaining Enfusion, Inc. position as of Q2 2025 after selling out during the quarter.
  • UBS Group sold 1,663,802 Enfusion, Inc. shares in Q2 2025, an estimated $18.6M.
  • UBS Group first reported a position in Enfusion, Inc. in Q4 2021 and held it in 13 quarters.
  • UBS Group's Enfusion, Inc. position peaked at $18.6M in Q1 2025.
  • 2 funds tracked by Wall St. Rank held Enfusion, Inc. as of Q2 2025.

Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.